Remibrutinib beat teriflunomide on relapse rates and every key secondary endpoint across the Phase 3 REMODEL studies, while avoiding the liver-safety signal that has complicated development of other BTK inhibitors.
AbbVie will present full Phase 3 CERVINO data for etentamig after the BCMA bispecific produced a 74% response rate and reduced progression or death risk by 60% in heavily pretreated multiple myeloma.
SMSbiotech has received an FDA “study may proceed” notification for a Phase 1b U.S. trial of nebulized allogeneic SMS Cells in COPD, with first dosing targeted for the fourth quarter.
The FDA has approved an IBTROZI label update incorporating a 49.7-month median duration of response from the TRUST-I study in TKI-naïve ROS1-positive NSCLC.
Eli Lilly will use the European Association for the Study of Diabetes 2026 meeting to detail Phase 3 retatrutide results, new Foundayo data and the first Phase 2 readout for eloraTZP, revealing how the company intends to segment an increasingly competitive obesity and diabetes market.
CMS has modernized Medicare coverage for transcatheter aortic valve replacement, ending evidence-development requirements for symptomatic severe aortic stenosis while creating a pathway for certain asymptomatic patients.
Stryker is extending its Prophecy patient-specific surgical planning platform, already used in more than 100,000 ankle cases, to the Incompass Total Ankle System as it builds a more connected Foot & Ankle ecosystem.
GE HealthCare has launched CareIntellect for Operations, an AI-enabled SaaS application designed to predict hospital capacity constraints up to 72 hours ahead and recommend actions around discharge, imaging, transfers and staffing.
The FDA has reduced monitoring requirements around the first two Imdelltra doses, lowering an important logistical burden days after Amgen reported positive Phase 3 survival data in first-line extensive-stage small cell lung cancer.
GSK’s licensed B7-H3 antibody-drug conjugate Ris-Rez delivered median survival of 18.5 months versus 10.3 months with topotecan in a Chinese Phase 3 study, strengthening the company’s case for global development.